Accessibility Menu
Bone Biologics logo

Bone Biologics(NASDAQ) BBLGW

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-73%
5 YearN/A
1 Year-36%
1 Month-34%
$9.53
-3.74%
-0.37Today
Bone Biologics last closing stock price
MetricPriceDate
Last closeUSD 9.532026-07-23
Bone Biologics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-34.28%USD 14.502026-07-13
1 month-34.28%USD 14.502026-06-22
3 month-52.33%USD 19.992026-04-24
Year to date-38.52%USD 15.502025-12-31
1 year-36.47%USD 15.002025-07-10
3 year+328.31%USD 2.232023-07-24
Since inception-73.31%USD 35.702021-10-13

Bone Biologics Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$2.86M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

0.17 (Low)

Price

$9.53

Volume

0

Open

$9.57

Previous Close

$9.53

Daily Range

$9.53 - $9.57

52-Week Range

$6.80 - $35.95

Estimated Earnings Date

Sep 2, 2026

BBLGW News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Bone Biologics

Bone Biologics Corporation is a medical device firm focused on advancing bone regeneration technologies, particularly for spinal fusion procedures. The company’s flagship product, NELL-1/DBX, combines an osteostimulative recombinant protein to enhance new bone formation, targeting degenerative disc disease in skeletally mature patients.

Products and Services
  • NELL-1/DBX Fusion Device for spinal fusion applications
  • Innovative solutions for general orthopedics and neurosurgery
  • Licensing agreement with UCLA for further development
Growth Outlook
  • Strong market potential in spinal fusion and orthopedic sectors
  • Ongoing advancements in NELL-1 technology for diverse applications
  • Strategic partnerships to enhance product development and commercialization
Financial Highlights
  • Cash and cash equivalents of $4.53 million as of March 31, 2026
  • Operating expenses of $805,054 in Q1 2026
  • Net income of -$765,988 for Q1 2026, reflecting ongoing investment in R&D
Bone Biologics Corporation is positioned in a growing market with its innovative approach to bone regeneration. The NELL-1/DBX Fusion Device aims to address significant medical needs in spinal fusion, with potential applications extending to various surgical disciplines. The company’s financial position, with substantial cash reserves, supports ongoing research and development efforts, indicating a commitment to innovation and market expansion. The strategic licensing agreement with UCLA further enhances the potential for successful commercialization of its technologies.
AI Generated • Jul 3, 2026

Industry

Biotechnology

Sector

Health Care

Headquarters

Burlington, MA 01803, US

BBLGW Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-50.45%

Return on Capital

-60.16%

Return on Assets

-57.40%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

0

Volume

0

Avg. Volume

412.516

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$3.00M

EBITDA

-$2.14M

Operating Cash Flow

-$2.57M

Capital Expenditure

-$5.00

Free Cash Flow

-$2.57M

Cash & ST Invst.

$4.53M

Total Debt

$0.00

Bone Biologics Performance Analysis

Bone Biologics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Bone Biologics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-315.6%
Q32025-09-3072.2%
Q42025-12-31-70.3%
Q12026-03-3131.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

2

N/A

Net Income

-$765.99K

+24.7%

EBITDA

-$765.99K

+24.7%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$4.53M

+64.9%

Total Debt

$0.00

N/A

Accounts Receivable

$7.81K

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-57.40%

N/A

Return on Invested Capital

-64.27%

N/A

Free Cash Flow

-$804.28K

+13.2%

Operating Cash Flow

-$804.28K

+13.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
NAOVNanoVibronix, Inc.
$1.90+1.06%
MOVECorvex, Inc.
$12.64+1.12%
VEROVenus Concept Inc.
$0.31+2.64%
DHAIDIH Holding US, Inc.
$0.02+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.25+0.10%
AALAmerican Airlines Group
$14.95+0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.24-0.02%
TAT&T
$24.42+0.01%

Questions About BBLGW

What is the current price of Bone Biologics?

Bone Biologics is trading at $9.53 per share.

What is the 52-week range for Bone Biologics?

Over the past 52 weeks, Bone Biologics has traded between $6.80 and $35.95.

How much debt does Bone Biologics have?

Bone Biologics total debt is unavailable.

How much cash does Bone Biologics have on hand?

Bone Biologics does not have cash on hand data available.

What is Bone Biologics’s dividend yield?

Bone Biologics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services